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100 PEY), the most common cause was IPF (5.4 per 100 PEY). 
The treatment discontinuation rate due to a TEAE was 17.9 
per 100 PEY; discontinuations were due to IPF (7.2 per 100 
PEY), pneumonia, respiratory failure, acute respiratory fail-
ure, rash (0.5 per 100 PEY each), and nausea (0.4 per 100 PEY). 
For patients from CAPACITY 004/006 who entered RECAP, 
the mean change in percent predicted forced vital capacity 
from RECAP baseline at 180 weeks was –9.6%. Median on-
treatment survival from the first pirfenidone dose in RECAP 
was 77.2 months.  Conclusions: RECAP provides long-term 
follow-up and safety data for pirfenidone that were consis-
tent with the known profile, with no new safety signals ob-
served.  © 2017 The Author(s)
Published by S. Karger AG, Basel 
 Introduction 
 Idiopathic pulmonary fibrosis (IPF) is a serious, dev-
astating, progressive, and often fatal fibrosing lung dis-
ease. Pirfenidone is an oral antifibrotic agent with anti-
inflammatory properties that was approved for the treat-
ment of IPF in the European Union in 2011 and in the 
United States in 2014. In the 2015 update of the American 
Thoracic Society, European Respiratory Society, Japanese 
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 Abstract 
 Background: RECAP (NCT00662038) was an open-label ex-
tension study in patients with idiopathic pulmonary fibrosis 
(IPF) who completed either the Assessment of Pirfenidone to 
Confirm Efficacy and Safety in Idiopathic Pulmonary Fibrosis 
(ASCEND) 016 phase 3 trial or the Clinical Studies Assessing 
Pirfenidone in Idiopathic Pulmonary Fibrosis: Research of Ef-
ficacy and Safety Outcomes (CAPACITY) 004/006 phase 3 tri-
als.  Objective: To obtain long-term safety data for pirfeni-
done in patients with IPF in RECAP.  Methods: Of the 1,334 
patients who participated in the phase 3 trials, 1,058 entered 
RECAP. The final analysis from enrollment (September 2008) 
to June 2015 is presented.  Results: Mean (SD) and median 
(range) pirfenidone exposures in RECAP were 122 (98) weeks 
and 88 (>0 to 349) weeks, respectively, with a mean daily 
dose of 2,091.1 mg. Cumulative total exposure was 2,482 pa-
tient exposure years (PEY). The treatment-emergent adverse 
event (TEAE) rate was 701.9 per 100 PEY. The serious TEAE 
rate was 53.5 per 100 PEY, with the most common serious 
TEAE being IPF (11.1 per 100 PEY). Of the 231 deaths (9.3 per 
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Respiratory Society, and Latin American Thoracic Asso-
ciation treatment guidelines for IPF, pirfenidone is con-
ditionally recommended for the treatment of IPF  [1] .
 In clinical trials, pirfenidone has slowed disease pro-
gression and decreased mortality compared with placebo, 
and observations of attenuated decline in lung function 
(forced vital capacity, FVC) from real-world data are con-
sistent with findings from clinical trials  [2–8] . Pirfeni-
done slowed disease progression as measured by changes 
in FVC  [9, 10] and reduced the risk of death from any 
cause by 48% at 1 year  [3, 11] . In addition, a treatment 
benefit for pirfenidone was observed for other outcomes, 
including 6-min walking distance and progression-free 
survival  [2, 11] .
 Pirfenidone has a favorable benefit-risk profile, with 
well-characterized long-term safety and tolerability data 
as well as manageable side effects  [12, 13] . Gastrointesti-
nal- and skin-related events, the most commonly report-
ed side effects from pirfenidone, are often manageable 
with appropriate mitigation strategies and education  [14, 
15] .
 RECAP was an open-label extension study evaluating 
the long-term safety of pirfenidone in patients with IPF 
who completed the Clinical Studies Assessing Pirfeni-
done in Idiopathic Pulmonary Fibrosis: Research of 
Efficacy and Safety Outcomes (CAPACITY) 006 (PIPF-
006; NCT00287729), CAPACITY 004 (PIPF-004; 
NCT00287716), or the Assessment of Pirfenidone to 
Confirm Efficacy and Safety in Idiopathic Pulmonary 
Fibrosis (ASCEND; PIPF-016; NCT01366209) trial  [16] . 
Here we present the primary analysis of the RECAP study.
 Methods 
 Patients 
 To be eligible for RECAP, patients had to have completed the 
final visit and not have permanently discontinued pirfenidone in 
a previous, qualifying phase 3 clinical trial (CAPACITY 004/006 
or ASCEND 016). Patients were to be enrolled in RECAP within 
10 days of completing the final visit in their qualifying trial. Enroll-
ment of CAPACITY 004/006 patients into RECAP was initiated 
nearly 4 years before the patients from ASCEND first entered 
RECAP.
 Study Design 
 RECAP (PIPF-012) was an open-label, multicenter, single-
arm, rollover study for patients with IPF who completed CAPAC-
ITY 004/006 or ASCEND. The primary objective was to obtain 
additional safety data for pirfenidone 2,403 mg/day. Patients en-
tering this study from any of the parent studies transitioned from 
one of three treatment arms: pirfenidone 1,197 mg/day (CAPAC-
ITY 004 only), pirfenidone 2,403 mg/day, or placebo. All patients 
were treated as if they had been receiving placebo during the phase 
3 trials due to patients entering RECAP before the unblinding in 
the parent study.
 Patients received pirfenidone 2,403 mg/day in equally divided 
doses three times per day with food  [17] . The pirfenidone dose was 
titrated from 801 mg/day over the first 15 days in RECAP to the 
maintenance dose of 2,403 mg/day or as high as was tolerated 
( ≤ 2,403 mg/day), depending on investigator judgment. The dura-
tion of treatment for each patient continued until pirfenidone be-
came commercially or otherwise available. Written informed con-
sent was required from all patients, and the study protocol was 
approved by the institutional review board or ethics committee at 
each center.
 Study Assessments 
 Patients were assessed via telephone at week 1. Physical exam-
ination and clinical laboratory assessments were performed at 
baseline and at weeks 2, 4, 6, and 12 and at 12-week intervals there-
after. A directed history, including a review of adverse events 
(AEs), serious AEs, concomitant medications, and treatment ad-
herence, was recorded at each visit. FVC, forced expiratory volume 
in 1 s, and diffusing capacity for carbon monoxide were measured 
at baseline and at week 12, then every 24 weeks. Week 8, 16, and 
20 visits were added for clinical lab assessments of liver chemistries 
when the patients from ASCEND entered the study.
 The analysis population consisted of all patients who were 
enrolled and received  ≥ 1 dose of pirfenidone. The primary anal-
ysis was based on data collected as of June 30, 2015, with 5 of the 
1,058 patients still ongoing. Assessments at each time point and 
their changes from baseline were summarized with descriptive 
statistics from all study visits, using all available data. Kaplan-
 Table 1.  Patient demographics and baseline characteristics (n = 
1,058)
Age, years 68.5 (7.47)
Age ≥65 years 745 (70.4%)
Male 790 (74.7%)
White 1,007 (95.2%)
Not Hispanic or Latino ethnicity 947 (89.5%)
Male weight, kg 88.3 (15.7)
Female weight, kg 73.6 (14.6)
Years since IPF diagnosis
<2 309 (29.2%)
2 to <4 572 (54.1%)
≥4 176 (16.7%)
For CAPACITY 004/006 patients only
FVC, % predicted 70.9 (16.68)
DLCO, % predicted1 41.2 (12.41)
 Values are presented as mean (SD) or n (%). Note that the 
collection of baseline assessments varied by parent study, but in 
general, baseline was defined as the last assessment before first 
dose. CAPACITY, Clinical Studies Assessing Pirfenidone in Id io-
pathic Pulmonary Fibrosis: Research of Efficacy and Safety Out-
comes; DLCO, diffusing capacity for carbon monoxide; FVC, 







Meier estimates were used to summarize time to early discon-
tinuation of pirfenidone. Efficacy data were collected on rollover 
patients from CAPACITY 004/006 through May 2012, when pa-
tients from ASCEND entered the study. No efficacy data were 
collected after that time because these data would not be compa-
rable due to differences in the study design between the ASCEND 
and CAPACITY 004/006 trials. Kaplan-Meier estimates were 
used to summarize survival time, as measured by time from the 
first dose of pirfenidone in RECAP to death (all-cause mortality). 
The annualized rate of decline in FVC volume was estimated us-
ing a random coefficient regression model (with random slopes 
and intercepts) that included sex, age, and height as covariates. 
The decrease in FVC was assumed to be linear within each pa-
tient. The intercepts and slopes were assumed to be normally dis-
tributed with an unstructured covariance matrix. The within-pa-
tient error was assumed to be independent and normally distrib-
uted with mean zero and a common variance. All observed FVC 
volumes from baseline were included in the model. Missing data 
were imputed implicitly by the model assuming missing at ran-
dom.
 The primary survival analysis was a treatment-emergent analy-
sis, in which all deaths occurring within 28 days after the last dose 
were included as events. Deaths occurring after the lung transplan-
tation date (if applicable) were excluded. Patients without events 
were censored at their lung transplantation date (if applicable), 
their last known alive date, or their last dose date plus 28 days, 
whichever was earlier.
 Safety data collected throughout the study included treat-
ment-emergent adverse events (TEAEs) and laboratory results. 
TEAEs were events occurring from the first dose in RECAP 
through 28 days after the last dose in RECAP. A dose interruption 
was defined as a dosing gap of  ≥ 1 day, excluding the initial dose 
escalation period. A drug holiday was defined as an interruption 
of  ≥ 14 days when the patient was not permanently discontinued 
from pirfenidone. Adverse drug reactions (ADRs) were AEs 
judged by the investigator as possibly or probably related to pir-
fenidone. AEs were summarized using patient incidence (defined 
as the number of patients with an event divided by total number 
of patients) and adjusted event rate per 100 patient exposure 
years (PEY) (defined as the number of events divided by the total 
PEY times 100).
 All authors participated in the design, conduct, and analysis of 
the study. The authors had full access to data, and no limits were 
placed on reporting of the results by the study sponsor.
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 Fig. 1. Patient disposition in RECAP. Patients who had received 
prior pirfenidone 1,197 mg/day, pirfenidone 2,403 mg/day, or pla-
cebo were enrolled into RECAP. ASCEND, Assessment of Pirfeni-
done to Confirm Efficacy and Safety in Idiopathic Pulmonary 
Fibrosis; CAPACITY, Clinical Studies Assessing Pirfenidone in 
Idiopathic Pulmonary Fibrosis: Research of Efficacy and Safety 
Outcomes.  * Patients were considered to have been on study if they 
were still in the study at the time the study was terminated.  † Pa-
tients were considered to have completed the study if they were 
active at the time their study site was closed due to availability of 
commercial pirfenidone or a posttrial access program. 




 Baseline Characteristics, Patient Disposition, and 
Pirfenidone Exposure 
 From the CAPACITY 004/006 and ASCEND trials, 
1,089 of 1,334 patients (81.6%) with IPF completed the 
study treatment. Between September 2008 and January 
2014, 1,058 of the 1,334 patients (79.3%) entered into 
RECAP (online suppl. Table 1; for all online suppl. mate-
rial, see www.karger.com/doi/10.1159/000479976).
 Patients in RECAP were mostly white (95.2%) and 
male (74.7%) and had an IPF disease duration between 2 
and 4 years (54.1%;  Table 1 ). For patients from the CA-
PACITY 004/006 trials at the start of RECAP, the baseline 
mean (SD) values for percent predicted FVC and percent 
predicted diffusing capacity for carbon monoxide were 
70.9% (16.68%) and 41.2% (12.41%), respectively.
 Of the 1,058 patients who entered RECAP, 427 pa-
tients (40.4%) had completed the study, 626 patients 
(59.2%) had discontinued it, and 5 patients in Mexico 
were still ongoing at the time of this analysis ( Fig. 1 ; June 
30, 2015). The 5 Mexican patients were all transferred to 
an alternative source of pirfenidone and discontinued 
from the study in February 2016. The median (95% CI) 
time to study discontinuation was 150 (132–166) weeks 
(online suppl. Fig. 1A).
 The mean (SD) and median (range) of pirfenidone ex-
posure in RECAP was 122 (98) weeks and 88 (>0 to 349) 
weeks, respectively, with a mean (SD) dose of 2,091.1 
(507.5) mg/day. The majority of patients (68.5%) received 
a mean daily dose of pirfenidone ranging from 2,200 to 
2,403 mg/day. The cumulative total exposure to pirfeni-
done was 2,482 PEY. Overall, 557 patients (52.6%) had a 
dose interruption, and 202 patients (19.1%) had  ≥ 3 dose 
interruptions. The median (range) duration of dose inter-
ruptions was 13 (1–320) days.
 Safety 
 The majority of patients (98.0%) reported  ≥ 1 TEAE. 
The most frequent TEAEs based on incidence were IPF 
(33.6%), cough (31.3%), and dyspnea (30.9%) ( Table 2 ). 
When adjusted for exposure, the most frequent TEAEs 
were IPF (22.0 per 100 PEY), upper respiratory infection 
(21.1 per 100 PEY), and bronchitis (19.5 per 100 PEY). 
TEAEs resulting in pirfenidone withdrawal occurred in 
444 patients (42.0%; 17.9 per 100 PEY;  Table 3 ) and in-
cluded 95 patients who died. The most frequent TEAE 
leading to pirfenidone withdrawal was IPF (16.8%; 7.2 per 
100 PEY). However, of the patients who discontinued the 
study due to an AE ( n = 358), 243 (67.9%) discontinued 
due to an AE unrelated to IPF progression (online suppl. 
Fig. 1B). These discontinuations resulting in study with-
drawal due to AEs other than IPF most often occurred 
during the first year of treatment (online suppl. Fig. 1B).
 ADRs occurred in 786 patients (74.3%). The most fre-
quent ADRs were nausea (21.6%; 11.6 per 100 PEY), diar-
rhea (12.3%; 6.9 per 100 PEY), and rash (11.6%; 7.2 per 
100 PEY), which were also observed in the phase 3 clinical 
trials (online suppl. Table 2). Discontinuation of pirfeni-
done due to an ADR occurred in 120 patients (11.3%; 4.8 
per 100 PEY) (online suppl. Table 3). The most frequent 
ADRs leading to discontinuation were rash (1.1%; 0.5 per 
100 PEY) and nausea (1.0%; 0.4 per 100 PEY).
 Severe or life-threatening TEAEs were reported in 597 
patients (56.4%), and the most frequent ones were IPF 
(23.0%), pneumonia (6.3%), and dyspnea (5.1%). Serious 
TEAEs were reported in 571 patients (54.0%), and the 
most frequent serious TEAEs were IPF (21.7%) and pneu-
monia (8.5%) ( Table 2 ).
 Table 2. Summary of TEAEs (n = 1,058)





TEAEs with incidence in ≥15% of patients
Total 1,037 (98.0) 17,422 701.9
IPF 355 (33.6) 547 22.0
Upper RTI 295 (27.9) 523 21.1
Bronchitis 260 (24.6) 485 19.5
Cough 331 (31.3) 436 17.6
Nausea 305 (28.8) 433 17.4
Dyspnea 327 (30.9) 420 16.9
Nasopharyngitis 202 (19.1) 359 14.5
Diarrhea 242 (22.9) 357 14.4
Fatigue 210 (19.8) 251 10.1
Dizziness 176 (16.6) 226 9.1
Serious TEAEs with incidence in ≥2% of patients
Total 571 (54) 1,329 53.5
IPF 230 (21.7) 276 11.1
Pneumonia 90 (8.5) 104 4.2
Bronchitis 32 (3.0) 38 1.5
Atrial fibrillation 26 (2.5) 32 1.3
Acute respiratory failure 30 (2.8) 30 1.2
Respiratory failure 29 (2.7) 29 1.2
IPF, idiopathic pulmonary fibrosis; PEY, patient exposure 
years; RTI, respiratory tract infection; TEAEs, treatment-emergent 
adverse events. 1 Adjusted rate per 100 PEY = (total number of 







 Death as the outcome of a TEAE was reported in 231 
patients (21.8%; 9.3 per 100 PEY) (online suppl. Table 4). 
The most frequent TEAEs that resulted in death were IPF 
(12.6%), respiratory failure (1.7%), and acute respiratory 
failure (1.0%). Deaths due to an ADR deemed as possibly 
related by investigators were reported in 13 patients 
(1.2%; 0.5 per 100 PEY) (online suppl. Table 5).
 Efficacy 
 In CAPACITY 004/006 patients entering RECAP with 
FVC data, the annualized rate (SD) of FVC decline was 
144.3 (6.0) mL using a linear mixed-effects model, which 
showed a slow decrease in FVC over the 180-week period 
(online suppl. Fig. 2). The median on-treatment survival 
from the first dose of 2,403 mg/day pirfenidone in RE-
CAP was 77.2 months ( Fig. 2 ).
 Discussion 
 This study evaluated safety outcomes in a large cohort 
of patients treated with pirfenidone 2,403 mg/day who 
had completed a previous phase 3 trial. RECAP provides 
long-term safety follow-up data for pirfenidone, with a 
cumulative total exposure of 2,482 PEY. At the time that 
patients from RECAP transitioned to commercially avail-
able pirfenidone or a posttrial access program, 40% were 
still receiving pirfenidone, after a median treatment dura-
tion in RECAP of 88 weeks (range >0 to 349 weeks).
 In contrast to the phase 3 clinical trials, the frequency 
and adjusted rate of ADRs were lower in RECAP (74.3%; 
133.7 per 100 PEY vs. 89.2%; 418.8 per 100 PEY). These 
results may be attributable to positive selection bias intro-
duced by extending observations in patients with prior 
chronic trial exposure to pirfenidone, which is a common 
issue in long-term extension studies. However, the most 
common ADRs observed in RECAP (nausea and rash) 
were consistent with those seen in the phase 3 clinical tri-
als and led to similar rates of discontinuation (1.0 vs. 1.1% 
and 1.1 vs. 1.4%, respectively)  [12] . Only 13 patients ex-
perienced an ADR that resulted in death, the most com-
mon ones being acute respiratory failure and IPF (2 each), 
which are indicative of the progressive nature of the dis-
ease. Overall, these data demonstrate that prolonged ex-
posure to pirfenidone does not increase the risk of ADRs, 
consistent with the known safety profile of pirfenidone.
 A total of 33.8% of patients discontinued RECAP due 
to AEs over the entire course ( ≥ 5 years) of the study. Most 
discontinuations (23.0%; online suppl. Fig. 1B) were due 
to AEs that were unrelated to IPF progression. These 
events occurred most frequently during the first year of 
treatment and in patients who were newly initiating pir-
fenidone (data not shown), suggesting that patients must 
be carefully monitored during this early treatment period 
to reduce the risk of discontinuation. Patient support 
programs have shown that early and careful management 
reduces the rate of discontinuations  [18] . While the over-
all discontinuation rate is higher than in the shorter phase 
3 trials, RECAP was a study conducted over several years, 
and IPF worsening did not appear to be the main driver 
for treatment discontinuations.
 Table 3. Summary of TEAEs resulting in pirfenidone withdrawal 
with incidence in ≥1% of patients (n = 1,058)





Total 444 (42.0) 444 17.9
IPF 178 (16.8) 178 7.2
Pneumonia 13 (1.2) 13 0.5
Respiratory failure 13 (1.2) 13 0.5
Acute respiratory failure 12 (1.1) 12 0.5
Rash 12 (1.1) 12 0.5
Nausea 11 (1.0) 11 0.4
IPF, idiopathic pulmonary fibrosis; PEY, patient exposure 
years; TEAEs, treatment-emergent adverse events. 1 Adjusted rate 
per 100 PEY = (total number of events/total years of exposure) × 












































Median survival = 72.2 months
 Fig. 2. On-treatment survival from the first dose of pirfenidone in 
RECAP (assume 1 month = 30.4375 days). 
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 The annual rate of FVC decline was 144.3 mL for pa-
tients who entered RECAP from CAPACITY 004/006 
(no efficacy measurements were acquired in the post-
ASCEND phase of the study), which was comparable to 
the 164-mL/year slope observed in the pirfenidone-treat-
ed patients in ASCEND and using a similar mixed-effects 
model for the calculation  [2] . In addition, the annual rate 
of FVC decline (mL) was similar for both prior pirfeni-
done-treated and prior placebo-treated patients from 
CAPACITY 004/006 who were treated with pirfenidone 
in RECAP, indicating that prior treatment did not appear 
to influence the annual rate of decline observed in RE-
CAP (data not shown). The median on-treatment sur-
vival from the first dose of pirfenidone 2,403 mg/day in 
RECAP was 77.2 months. These data reinforce/support 
the long-term efficacy of pirfenidone and suggest that the 
treatment benefit of pirfenidone was maintained in pa-
tients who continued receiving therapy.
 These results of this study should be interpreted in the 
context of some limitations because of its open-label, un-
controlled design with no applicable sample size and pow-
er calculations, as well as the inherent biases in the study, 
including the survival bias for patients in RECAP who did 
not die in the previous phase 3 studies; in addition, the 
vital status of patients who discontinued RECAP was not 
captured at the end of RECAP as was done in ASCEND/
CAPACITY 004/006. Patients who did not tolerate pir-
fenidone were not eligible for RECAP because patients 
were required to have completed their previous phase 3 
study and were generally compliant with study treatment. 
Although reasons for not rolling over into RECAP were 
also not collected, the majority of patients (1,058 of 1,089; 
97.2%) who completed ASCEND/CAPACITY 004/006 
while on treatment enrolled into RECAP.
 The long-term safety results from this study are con-
sistent with the known safety profile of pirfenidone, with 
no new safety signals observed. These findings support 
the clinical use of pirfenidone in patients with IPF.
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